I-MED Pharma, Inc. announces commercial the launch of the i-Pen®, its new tear osmolarity device, for the diagnosis of Dry Eye Disease (DED).
Online PR News – 06-May-2016 – Montreal, QC – I-MED Pharma, Inc., a Canadian eye care company, announced today the global launch of its new medical device, the i-Pen®, intended to compete in and to expand the dry eye disease (DED) diagnostic market.
The i-Pen® is a hand-held device designed for an easy, quick and accurate measurement of tear osmolarity derived from ocular tissues. Daniel Hofmann, Vice-President of I-MED Pharma, commented, "The i-Pen® represents a new generation of truly affordable and easy to use technology to assess dry eye disease. We are excited about the opportunities the i-Pen® platform provides for clinicians and for their patients by giving them an accurate and reliable quantitative measure of DED. From the start our goal was to make this important diagnostic tool easily accessible to all healthcare professionals to help them diagnose and target dry eye treatments for their patients."
Hofmann estimates that their business model will allow clinicians to recover their capital costs with fewer than forty patients. He anticipates that the i-Pen® will be submitted to FDA in 2016 and that it will not require a CLIA waiver. In response to the patent infringement lawsuit filed in Canada by TearLab Corporation (NASDAQ:TEAR), headquartered in California, in February 2016, he stated, "It is I-MED Pharma's position that it will not comment on pending litigation except to say that we deny infringement and we will contest the validity of the TearLab patent at issue."
About I-MED Pharma, Inc.
I-MED Pharma is a privately held Canadian company that designs, manufactures and distributes medical, surgical and veterinary eye care products. For more information, please visit www.imedpharma.com.